LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Xiaozheng Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cellular Senescence, Radiation Tolerance, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Radiotherapy (RT) in non-small cell lung cancer (NSCLC) triggers cellular senescence, complicating tumor microenvironments and affecting treatment outcomes. This study examines the role of lymphocyte immunoglobulin-like receptor B2 (LILRB2) in modulating RT-induced senescence and radiosensitivity in NSCLC. Through methodologies including irradiation, lentivirus transfection, and various molecular assays, we assessed LILRB2's expression and its impact on cellular senescence levels and tumor cell behaviors. Our findings reveal that RT upregulates LILRB2, facilitating senescence and a senescence-associated secretory phenotype (SASP), which in turn enhances tumor proliferation and resistance to radiation. Importantly, LILRB2 silencing attenuates these effects by inhibiting the JAK2/STAT3 pathway, significantly increasing radiosensitivity in NSCLC models. Clinical data correlate high LILRB2 expression with reduced RT response and poorer prognosis, suggesting LILRB2's pivotal role in RT-induced senescence and its potential as a therapeutic target to improve NSCLC radiosensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, S…
- Clinical College of Medicine, Jining Medical University, Jining, Shandong, China.
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Electronic address: wanglinlinatjn@163.com.
Zitieren
APA
Chen, X., Yuan, M., Zhong, T., Wang, M., Wu, F., Lu, J., Sun, D., Xiao, C., Sun, Y., Hu, Y., Wu, M., Wang, L., Yu, J., & Chen, D. (2024). LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216930
Vancouver
Chen X, Yuan M, Zhong T, Wang M, Wu F, Lu J, et al. LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216930
BibTeX
@article{Chen2024,
author = {Chen, Xiaozheng and Yuan, Meng and Zhong, Tao and Wang, Minglei and Wu, Fei and Lu, Jie and Sun, Dongfeng and Xiao, Changyan and Sun, Yuping and Hu, Yun and Wu, Meng and Wang, Linlin and Yu, Jinming and Chen, Dawei},
title = {LILRB2 inhibition enhances radiation sensitivity in non-small cell lung cancer by attenuating radiation-induced senescence},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216930}
}
EUVIMED